Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cantargia reports new positive preclinical efficacy data for CAN10 supporting development in myocarditis

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data from a collaboration with Johns Hopkins University School of Medicine demonstrating efficacy of CAN10 in a viral myocarditis model. The results highlight the potential of CAN10 in the treatment of this common form of myocarditis ahead of planned clinical trials. The data will be presented in a poster session at one of the world’s largest meetings on innovations in cardiac health, the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2022, being held in Chicago, July 25-28, 2022.The IL1RAP-binding

Buy-back of shares in Hemnet during 18 - 22 July, 2022

Hemnet Group AB (publ) (LEI code: 5493008VIU67J3HUAR07) ("Hemnet") has during 18 to 22 July 2022 repurchased in total 129,500 own ordinary shares (ISIN code: SE0015671995) as part of the share buy-back program initiated by the board of directors of Hemnet in order to adjust Hemnet's capital structure.The share buy-backs form part of the share buy-back program of maximum SEK 450,000,000 announced by Hemnet on 13 May 2022. The share buy-back program is being carried out in accordance with the EU Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) 2016/

Buybacks of series B shares in AB Electrolux during week 29, 2022

During the period July 18 – July 22, 2022 AB Electrolux (LEI code 549300Y3HHZB1ZGFPJ93) has repurchased in total 269,645 own series B shares (ISIN: SE0016589188) as part of the buyback program initiated by the Board of Directors in order to optimize the company’s capital structure.The share buybacks form part of the buyback program of a maximum of 8,000,000 series B shares for a total maximum amount of SEK 1,250 million, which AB Electrolux announced on April 29, 2022. The buyback program, which runs between May 2, 2022 – October 21, 2022, is being carried out in accordance with the Market

Buybacks of shares of series B in Trelleborg during week 29, 2022

During the period July 18 to July 22, 2022, Trelleborg AB (LEI code 213800XY16PAWG2PAD14) has repurchased in total 751,410 own shares of series B (ISIN: SE0000114837) as part of the buyback program initiated by the Board of Directors in order adapt the company’s capital structure and thereby contribute to increased shareholder value.   The share buybacks form part of the buyback program of a maximum of 25,272,178 shares of series B for a total maximum amount of SEK 5,000 million, which Trelleborg announced on April 27, 2022. The buyback program, which runs between April 28, 2022, to

Tuomas Jylhä joins Eevia Health Plc as Interim Chief Financial Officer

Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.Tuomas Jylhä comes from the position of Financial Manager at Rantalainen, a financial administration services firm, with over 1,100 experts in 50 locations in Finland. Tuomas Jylhä has a Master’s degree in economics and a professional background in banking and auditing. He is based

Buybacks of shares by H&M during week 29, 2022

Between 18 July 2022 and 22 July 2022 H & M Hennes & Mauritz AB (publ) (LEI code 529900O5RR7R39FRDM42) has repurchased in total 966,200 own B shares (ISIN: SE0000106270) as part of the share buyback programme initiated by the board of directors.The share buybacks form part of the SEK 3.0 billion share buyback programme that H&M announced on 29 June 2022. The share buyback programme, which runs between 29 June 2022 and 30 November 2022, is being carried out in accordance with Regulation (EU) No 596/2014 on market abuse (the Market Abuse Regulation – MAR) and Commission Delegated Regulation (

Moobifun Signs Deal to Digitise Grupo Pefaco’s Casino Operation in Africa

Moobifun , a leading turnkey iGaming solutions provider, has agreed a deal with Grupo Pefaco to digitise its casino operations within Africa.Grupo Pefaco runs several successful casino businesses in West Africa and Moobifun will be spearheading the online migration using its standout proprietary technology. Focus will initially be on digitising Grupo Pefaco’s casinos across six African countries.  Moobifun will enable Grupo Pefaco to engage with its customers via the best localised mobile channels for each individual market. Furthermore, Moobifun is to provide its

Sandvik wins record SEK 330 million order for battery-electric mining equipment

Sandvik has been awarded an order to supply a fleet of battery-electric trucks, loaders, drills and on-site service support for Foran Mining’s McIlvenna Bay project in Saskatchewan, Canada, which is designed to be the world’s first carbon neutral copper development project. The order, valued at SEK 330 million, is Sandvik’s largest to date for battery-electric equipment, and will be booked in the third quarter.   Under the contract Sandvik will supply a fleet of 20 battery-electric vehicles as well as Battery as a Service. The delivery of the equipment is scheduled to take place

Firearms expert honoured with Outstanding Alumni Award

A leading firearms expert from Staffordshire University has been honoured with a prestigious award from the university where she studiedDr Rachel Bolton-King was awarded an Outstanding Alumni Award from Nottingham Trent University during its graduation celebrations last week. The award recognises the vital role that former students play in raising the university’s profile through their distinctive attainments, professional success and contributions to society. Rachel, who is an Associate Professor of Forensic Science and Editor-in-Chief of journal Science & Justice, was honoured for her

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 133 - 25 JULY 2022  In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 117/2022.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor Communications Partner, tel.: 3315 0451

DAMPSKIBSSELSKABET NORDEN A/S – weekly report on share buy-back

ANNOUNCEMENT NO. 132 - 25 jULY 2022 On 6 July 2022, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 6 July 2022 up to and including no later than 16 August 2022. For details, please see announcement no. 117 of 6 July 2022.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 15 million (approximately DKK 106 million). Under the

Trelleborg’s magazine T-Time – about solutions that seal, damp and protect critical applications

Trelleborg’s magazine T-Time has shifted to an online format and will no longer be printed and distributed by post to shareholders and other stakeholders. The online format lessens the environmental impact and takes advantage of the opportunities created by digitization and interactivity.   In the July edition one can read about:   A safe crossing Trelleborg’s sealing systems for immersed tunnels, with a life expectancy of 120 years, protect infrastructure against water ingress, ground movements and water pressure.   Keyhole surgery for pipes Customized solutions for

SimCorp A/S – Share buyback program

Company Announcement no. 34/2022On February 15, 2022 SimCorp A/S announced a share buyback program in compliance with the provisions of Regulation No. 596/2014 of the European Parliament and of the Council on market abuse (the Market Abuse Regulation - MAR) and delegated legislation under MAR. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 20.0m, to be executed during the period from February 15, 2022 to July 31, 2022. The following transactions have been executed under the program:          Date                 Number of shares

Outokumpu – Announcement regarding change in holdings

Outokumpu OyjStock exchange releaseJuly 25, 2022 at 10.45 am EESTOutokumpu – Announcement regarding change in holdings Outokumpu Oyj (business identity code: 0215254-2) has on July 22, 2022 received a notification based on Chapter 9, Section 5 of the Finnish Securities Market Act. Société Générale SA’s total holding in the shares and voting rights of Outokumpu has risen above 5% threshold and was 5.03% on July 21, 2022. Their earlier holding in the Outokumpu shares and voting rights was below minimum threshold. Total direct andindirect holdingsof SociétéGénérale SA

Company Announcement No. 83, 2022 – Debtor composition in Nordea Kredit (CK 92)

Monthly information on debtor composition in Nordea Kredit published in order to comply with the Transparency Directive's disclosure requirements.Nordea Kredit hereby publishes monthly data on debtor composition of all callable bond series. The information is subject to disclosure requirements in the Securities Trading Act § 27a section 1.The information is also published in the usual way via the Copenhagen Stock Exchange / OMX.   Nordea Kredit Realkreditaktieselskab   Klaus Johnbeck Phone : +45 55 47 05 11

Risk Intelligence A/S secures funding package

Risk Intelligence A/S (“Risk Intelligence” or "Company") has secured a loan funding package to provide capital for increased commercial initiatives and for general liquidity.During July and ending today 25 July, Risk Intelligence has secured a DKK 5.5M funding package in loans from private lenders of 3, 6, and 9 months duration, and at an interest rate of 12% PA. Some of the loans have an option to be renewed pending mutual agreement. The lenders are shareholders of Risk Intelligence A/S. This funding model was selected as other sources of funding were found to be more costly and with

iLOQ opens a new sales office in Poland

iLOQ, a provider of digital access management solutions, will continue to fulfill its growth strategy by expanding to Poland. Founded in Finland in 2003, iLOQ currently has sales offices in 9 countries throughout Europe, operations in Canada and a partner network around the world. Adding Poland to its portfolio continues to fulfill the Company’s growth strategy and allows iLOQ to introduce the benefits of its battery-free digital-locking and mobile-access-sharing technology to a new market. Grzegorz Korzeniowski has been appointed Country Manager in Poland. He will be

Preliminary study to detect immune complex and complement deposits in renal biopsies initiated with the University Hospitals Coventry and Warwickshire in the UK

A proof of concept-study to explore the potential of Lumito's UCNP to detect immune complex and complement deposits in renal biopsies has been initiated in collaboration with University Hospitals Coventry and Warwickshire NHS Trust in the UK and a research team led by Dr. Kishore Gopalakrishnan.Obtaining a renal biopsy is an invasive procedure but is nevertheless an important part of the management of renal disease. The diagnostic algorithm includes the detection of immunoglobulin and complement deposits in the kidney, primarily in the glomeruli. The conventional and well-established

Wulff Group Plc’s Half-Year Financial Report for January 1 – June 30, 2022

HALF-YEAR FINANCIAL REPORT | JULY 25, 2022 AT 9.30 A.M. This is a summary of Wulff Group Plc’s half-year financial report for January-June 2021. Wulff Group’s half-year financial report as a whole is attached as a PDF file to this stock exchange release and it is also available on the company’s website wulff.fi/en . Sales growing in the Nordic markets 1.4.–30.6.2022 BRIEFLY · Net sales increased in the Nordic countries in the Contract Customers Segment; domestically, net sales of international exhibition services and financial administration services

Bioservo receives a major customer order in the USA corresponding to SEK 1.6 million

Via the distributor Rhino Tool House, Bioservo Technologies AB has received a significant commercial order from Waupaca Foundry for 30 Ironhand® systems for an order value of SEK 1.6 million. The order is part of an implementation project where Bioservo together with the distributor Rhino Tool House, during six months, will validate the product for a wider implementation within the foundry industry.Waupaca Foundry is a leading supplier of iron castings and operates six iron foundries in North America. Many of the work steps in a foundry are manual and demanding for the workers. At Waupaca

Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma

First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations.AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the PATHFINDER

Tezspire recommended for EU approval in asthma

25 July 2022 07:10 BST Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations AstraZeneca's Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. The Committee for Medicinal Products

Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis

First and only long-acting C5 complement inhibitor showed early effect and demonstrated clinical improvement in activities of daily living.Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AChR antibody-positive gMG in the EU. The Committee for

There are no items matching the current filter
There are no more items matching the current filter
Back to top